Seattle Genetics (NASDAQ:SGEN) announced its earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08, Stock Ratings Network reports. The company had revenue of $68.30 million for the quarter, compared to the consensus estimate of $64.62 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 19.2% on a year-over-year basis. Seattle Genetics, Inc. (NASDAQ:SGEN) shares after opening at $37.50 moved to $37.50 on last trade day and at the end of the day closed at $34.50. Company price to sales ratio in past twelve months was calculated as 15.77 and price to cash ratio as 11.35. Seattle Genetics, Inc. (NASDAQ:SGEN) showed a negative weekly performance of -7.88%.
Molecular diagnostic testing and genetics company, Sequenom Inc. (NASDAQ:SQNM) surged after beating estimates with its first quarter results, having posted record revenues. Sequential growth continues to be experienced in better than expected volumes of revenue, gross margin and expenses. Steady growth continue to ensure the company reaches desirable profit volumes at the back of impressive efforts from the sales team and the management team. Sequenom, Inc. (NASDAQ:SQNM) shares advanced 8.57% in last trading session and ended the day on $2.90. SQNM return on equity ratio is recorded as 698.50% and its return on assets is -58.80%. Sequenom, Inc. (NASDAQ:SQNM) yearly performance is -19.22%.
RXi Pharmaceuticals Corp (NASDAQ:RXII) announced obtaining positive results from the evaluation of connective tissue growth factor (CTGF) levels of protein after injecting RXI-109 intravitreaously in cynomolgus monkeys’ eyes.The treatment involving the intravitreal injection of the RXI-109 was a part of a study of amount of dosage to establish RXi Pharmaceuticals’ franchise. RXi Pharmaceuticals Corp (NASDAQ:RXII) focuses primarily on finding, developing and distributing novel treatment options catering major unaddressed or unsatisfied medical requirements with the use of RNA based technologies. RXi Pharmaceuticals Corp (NASDAQ:RXII) shares moved up 6.62% in last trading session and was closed at $3.32, while trading in range of $ 3.23 – 4.30. RXi Pharmaceuticals Corp (NASDAQ:RXII) year to date (YTD) performance is 16.65
Shares of Endocyte (NASDAQ:ECYT) saw strong trading volume on Friday after the company announced better than expected quarterly earnings, American Banking and Market News reports. 13,778,961 shares changed hands during trading, an increase of 624% from the previous session’s volume of 1,903,723 shares. The stock last traded at $6.70 and had previously closed at $17.38. Endocyte, Inc. (NASDAQ:ECYT) weekly performance is -63.10%. On last trading day company shares ended up $6.62. Endocyte, Inc.(NASDAQ:ECYT) distance from 50-day simple moving average (SMA50) is -63.67%. Analysts mean target price for the company is $42.19.